The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) this week for the use of BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2. The test is the second antigen diagnostic to earn emergency use authorization from the FDA and can be used in patient care settings approved for Clinical Laboratory Improvement Amendments of 1988 for high or moderate complexity or waived testing. However, the test’s emergency use is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.